However, about 25% of HER2+ breast cancers do not initially respond to TRZ [4], and 70% of TRZ-responsive metastatic cancers progress despite treatment within the first year due to the acquisition of resistance to TRZ [5]. This evidence concerns the gene ERBB2 and breast carcinoma.